193 related articles for article (PubMed ID: 15264993)
21. [Anagrelide in control of myeloproliferative thrombocythemia: long-term experiences in 6 patients].
Burkhard R; Adam H; Widmer L; Honegger HP
Schweiz Med Wochenschr; 1998 Nov; 128(46):1808-12. PubMed ID: 9857387
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of cytoreductive therapies in patients with essential thrombocythaemia aged >80 years: an interim analysis of the EXELS study.
Kiladjian JJ; Besses C; Griesshammer M; Gugliotta L; Harrison C; Coll R; Smith J; Birgegård G
Clin Drug Investig; 2013 Jan; 33(1):55-63. PubMed ID: 23184668
[TBL] [Abstract][Full Text] [Related]
23. Characterization of different regimens for initiating anagrelide in patients with essential thrombocythemia who are intolerant or refractory to their current cytoreductive therapy: results from the multicenter FOX study of 177 patients in France.
Rey J; Viallard JF; Keddad K; Smith J; Wilde P; Kiladjian JJ;
Eur J Haematol; 2014 Feb; 92(2):127-36. PubMed ID: 24118452
[TBL] [Abstract][Full Text] [Related]
24. Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Anagrelide Study Group.
Am J Med; 1992 Jan; 92(1):69-76. PubMed ID: 1731512
[TBL] [Abstract][Full Text] [Related]
25. Treatment of essential thrombocythemia with anagrelide.
Chintagumpala MM; Kennedy LL; Steuber CP
J Pediatr; 1995 Sep; 127(3):495-8. PubMed ID: 7658287
[TBL] [Abstract][Full Text] [Related]
26. Role of platelet counts in the management of essential thrombocythemia: experience with anagrelide.
Griesshammer M
Expert Rev Hematol; 2009 Jun; 2(3):227-36. PubMed ID: 21082965
[TBL] [Abstract][Full Text] [Related]
27. Treatment of essential thrombocythemia with anagrelide.
Silverstein MN; Tefferi A
Semin Hematol; 1999 Jan; 36(1 Suppl 2):23-5. PubMed ID: 9930554
[TBL] [Abstract][Full Text] [Related]
28. [Anagrelide in the treatment of essential thrombocythemia (ET) and other myeloproliferative disorders with thrombocythemia based on data from patient register in the CR].
Penka M; Doubek M; Schwarz J; Pytlík R; Dulícek P; Kissová J; Hlusí A; Vozobulová V; Cerná O; Brychtová Y; Szotkowski T; Volková Z; Seghetová J; Schutzová M; Hadacová I; Hochová I; Voglová J; Siroký O; Belada D; Lhot'anová T; Bubeník B; Vránová M; Micaníková M; Dusek L
Vnitr Lek; 2006 May; 52(5):498-503. PubMed ID: 16771099
[TBL] [Abstract][Full Text] [Related]
29. [Essential thrombocythaemia and other myeloproliferative disorders with thrombocythaemia treated with Thromboreductin. A report from the database of register for the 1st quarter of 2010].
Penka M; Schwarz J; Ovesná P; Hlusí A; Korístek Z; Doubek M; Dulícek P; Pospísilová D; Kissová J; Buliková A; Pavlík T;
Vnitr Lek; 2010 Jun; 56(6):503-12. PubMed ID: 20681462
[TBL] [Abstract][Full Text] [Related]
30. Management of refractory essential thrombocythemia with anagrelide in a patient undergoing hemodialysis.
Mesquita Mdo C; Sol EB; Malarme M; Noubouossie D; Demulder AC
Clin Ther; 2009 Nov; 31(11):2559-64. PubMed ID: 20110000
[TBL] [Abstract][Full Text] [Related]
31. [The effectiveness of anagrelide treatment in patients with Ph negative myeloproliferative diseases: influence on the incidence of thrombosis in the data from the Registry of patients with essential thrombocythemia and thrombocythemia associated with other myeloproliferative diseases treated with Thromboreductin® to the end of 2012].
Penka M; Schwarz J; Ovesná P; Cervinek L; Dulíček P; Pospíšilová D; Kissová J; Pavlík T;
Vnitr Lek; 2013 Jun; 59(6):516-31. PubMed ID: 23808749
[TBL] [Abstract][Full Text] [Related]
32. [Essential thrombocythemia: therapy with anagrelide].
Mazzucconi MG; Ferrari A; Balduini CL
Haematologica; 1991 Jun; 76 Suppl 3():378-81. PubMed ID: 1661268
[No Abstract] [Full Text] [Related]
33. Modifying the Effects of Cytoreductive Drugs on Kidney Function in Myeloproliferative Neoplasms.
Krečak I; Lucijanić M
Pharmacology; 2021; 106(7-8):451-452. PubMed ID: 34139702
[No Abstract] [Full Text] [Related]
34. Combination therapy of hydroxycarbamide with anagrelide in patients with essential thrombocythemia in the evaluation of Xagrid(R) efficacy and long-term safety study.
Gugliotta L; Besses C; Griesshammer M; Harrison C; Kiladjian JJ; Coll R; Smith J; Abhyankar B; Birgegård G
Haematologica; 2014 Apr; 99(4):679-87. PubMed ID: 24334294
[TBL] [Abstract][Full Text] [Related]
35. Anagrelide for the treatment of thrombocythaemia in daily clinical practice: a post-marketing observational survey on efficacy and safety performed in Germany.
Schmitz S; Stauch M; Schlag R
Onkologie; 2010; 33(1-2):39-44. PubMed ID: 20164660
[TBL] [Abstract][Full Text] [Related]
36. Anagrelide: a novel agent for the treatment of myeloproliferative disorders.
Pescatore SL; Lindley C
Expert Opin Pharmacother; 2000 Mar; 1(3):537-46. PubMed ID: 11249536
[TBL] [Abstract][Full Text] [Related]
37. [Treatment of essential thrombocythemia with anagrelide: a ten-year experience].
Kornblihtt LI; Vassallu PS; Heller P; Molinas FC
Medicina (B Aires); 2002; 62(3):231-6. PubMed ID: 12150005
[TBL] [Abstract][Full Text] [Related]
38. Studies of platelet volume, chemistry and function in patients with essential thrombocythaemia treated with Anagrelide.
Bellucci S; Legrand C; Boval B; Drouet L; Caen J
Br J Haematol; 1999 Mar; 104(4):886-92. PubMed ID: 10192455
[TBL] [Abstract][Full Text] [Related]
39. Anagrelide reduces thrombotic risk in essential thrombocythaemia vs. hydroxyurea plus aspirin.
Dombi P; Illés Á; Demeter J; Homor L; Simon Z; Karadi E; Udvardy M; Egyed M
Eur J Haematol; 2017 Feb; 98(2):106-111. PubMed ID: 27557754
[TBL] [Abstract][Full Text] [Related]
40. A critical review of anagrelide therapy in essential thrombocythemia and related disorders.
Dingli D; Tefferi A
Leuk Lymphoma; 2005 May; 46(5):641-50. PubMed ID: 16019501
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]